Key points are not available for this paper at this time.
Balances risks in complex interventions; leaves open optimal strategies for prospective trials.
Jack WC Tan reports honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Alvimedica, Boehringer Ingelheim, and Pfizer; research and educational grants from Medtronic, Biosensors, Biotronik, Philips, Amgen, AstraZeneca, Roche, Otsuka, Terumo, and Abbott Vascular; and consulting fees from Elixir and CSL Behring. Sidney TH Lo reports lecture honoraria from Bristol-Myers Squibb, Bayer, and Boehringer-Ingelheim; proctorship fees from Abbott, Boston Scientific, and Bioexcel; research funding from Abbot; and is an advisory board member for Abbott and Medtronic. Derek P Chew reports consulting fees from APSC; support for travel to meetings for the study or otherwise from APSC; grants/grants pending from Roche Diagnostics and AstraZeneca; and payment for development of educational presentations including service on speakers' bureaus from AstraZeneca.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: